Leerink Swann Upgrades Regeneron Pharma (REGN) to Outperform; Shares Back to Decent Levels
Tweet Send to a FriendGet Alerts REGN Hot Sheet
Price: $254.87 --0%
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 5
Rating Summary:
12 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 5
Trade REGN Now!
Leerink Swann upgraded Regeneron Pharma (NASDAQ: REGN) from Market Perform to Outperform.
Leerink analyst says, "REGN shares continue to be volatile, returning to the levels where we first initiated after reaching the $70s when infections were reported with off-label Avastin. With the 2nd year of VIEW data around the corner representing a significant binary event, we believe current levels offer a decent entry point on a risk-adjusted basis."
"We estimate 50% upside if Eylea beats by >1.5 injections (15% probability); 25% upside if Eylea beats by 0.5-1.5 injections (45% probability); 20% downside if Eylea is as good as Lucentis (30% probability) and 35% downside if Eylea is worse than Lucentis (10% probability)."
For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $57.09 yesterday, with a 52 week range of $24.29-$79.90.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Leerink analyst says, "REGN shares continue to be volatile, returning to the levels where we first initiated after reaching the $70s when infections were reported with off-label Avastin. With the 2nd year of VIEW data around the corner representing a significant binary event, we believe current levels offer a decent entry point on a risk-adjusted basis."
"We estimate 50% upside if Eylea beats by >1.5 injections (15% probability); 25% upside if Eylea beats by 0.5-1.5 injections (45% probability); 20% downside if Eylea is as good as Lucentis (30% probability) and 35% downside if Eylea is worse than Lucentis (10% probability)."
For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $57.09 yesterday, with a 52 week range of $24.29-$79.90.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
- RBC Capital Upgrades Pandora (P) to Outperform
- Topeka Capital Upgrades Pacific Sunwear of California (PSUN) to Buy
Create E-mail Alert Related Categories
Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
